3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its over-the-counter (OTC) drug, a 5% minoxidil foam agent, which is indicated for the treatment of male pattern hair loss and alopecia areata.
Minoxidil is recognized as the first-line topical treatment for male pattern hair loss. 3SBio’s product stands out with its enhanced penetration speed and accumulation rate under the scalp, resulting in milder scalp tolerance. This marks the first time such a product has been granted marketing approval in China. Results from a multi-center, double-blind, randomized controlled clinical study have demonstrated that the efficacy of 3SBio’s minoxidil foam is equivalent to that of the control drug ROGAINE, meeting the preset statistical endpoint in male pattern alopecia patients.- Flcube.com
